Terence Novak has been appointed chief operating officer at specialty drug maker Pernix Therapeutics Holdings Inc.


Pernix Therapeutics Holdings, Terence Novak, chief operating officer, COO, Norwich Pharma Services, Doug Drysdale, pharmaceutical industry, specialty pharmaceutical company












































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Pernix Therapeutics hires COO

March 10th, 2014

HOUSTON – Terence Novak has been appointed chief operating officer at specialty drug maker Pernix Therapeutics Holdings Inc.

Pernix said Monday that Novak joins the company from Norwich Pharma Services, where he most recently served as president and helped establish Norwich as a leader in the contract development and manufacturing industry, focused on specialty pharmaceuticals.

"Terry will be working closely with our network of suppliers and manufacturers to ensure that our customers continue to receive high-quality products to meet their needs. I am pleased to add an executive of Terry's caliber to our leadership team, and I look forward to working with him again" stated Doug Drysdale, president and chief executive officer of Pernix.

Pernix noted that Novak brings over 30 years of pharmaceutical industry experience, including 20 years in executive leadership in business development, sales, marketing and operations. During that time, he led the creation of over 75 sales forces and sales operations teams and managed multiple product launches.

"I am very excited to be joining Pernix and to work with Doug and the executive team to build on the existing infrastructure and create an efficient, high-quality specialty pharmaceutical company," Novak commented. 

Pernix's portfolio of branded products includes Cedax, an antibiotic for middle ear infections, along with treatments for cough and cold conditions, including ZutriPro, Rezira and Vituz. The company also markets Silenor, a non-narcotic product for the treatment of insomnia.

Advertisement